Peter Hansen Moderna ( NASDAQ: MRNA ), the only company to market a messenger RNA-based vaccine against the respiratory syncytial virus (RSV), will soon face competition from China as regulators in the country have just cleared clinical trials for a rival shot from CSPC Pharmaceutical Group ( OTCPK:CSPCY ). The Hong Kong-listed company said Thursday that China’s National Medical Products Administration (NMPA) approved clinical trials for its mRNA-based RSV vaccine candidate, SYS6016. The vaccine is designed to prevent lower respiratory tract disease (LRTD) caused by RSV infections.
Shijiazhuang-based CSPC ( OTCPK:CHJTF ) said that SYS6016 has already undergone preclinical trials, neutralizing both RSV-A and RSV-B strains of the virus with a favorable safety profile. “The Group will endeavour to advance the clinical research of the product and strive to market the product as soon as possible so as to create value for the society and shareholders,” the company added. The RSV vaccine market is currently dominated by Pfizer ( PFE ) and GSK ( GSK ), which won FDA approvals last year for their more traditionally developed shots, Arexvy and Abrysvo.
Moderna ( MRNA ) officially entered the race in June when the FDA cleared its mRNA-based vaccine mRESVIA to protect older adults from developing LRTD caused by RSV. More on CSPC Pharmaceutical, Moderna, etc. Moderna: Really Strong Competition Moment Of Truth Approaches For Moderna's RSV Vaccine Moderna, Inc.
(MRNA) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Moderna, Mitsubishi Tanabe enter JV to promote mRNA respiratory, COVID-19 shots in Japan COVID infections could be seeing a summer surge based on CDC data.
